Sage Journals: Discover world-class research

Abstract

In November, 1989, the Centers for Disease Control (CDC) began receiving reports of a rare condition called Eosinophilia-Myalgia Syndrome (EMS) in individuals known to be taking the amino acid L-tryptophan (LT). The association between LT and EMS came as a surprise to physicians and scientists because LT is an essential amino acid present in the diet and has been available as a nutritional supplement, without a prescription, since the 1960s. However, despite a recall of LT products instituted by the Food and Drug Administration (FDA), as of July 5, 1991, 1,543 cases of EMS, including 31 deaths, have been reported to the CDC. This paper discusses the manufacturing, scientific, and regulatory issues which led to the EMS epidemic and recommends that regardless of how a substance is regulated, its purity be monitored and ensured by a responsible scientific or regulatory agency in order to protect the health of the public.

Keywords

L-Tryptophan Eosinophilia-Myalgia Syndrome Regulation of amino acids as nutritional supplements

Get full access to this article

View all access options for this article.

References

Centers for Disease Control.

Eosinophilia-Myalgia Syndrome — New Mexico. MMWR. 1989;38(45):765–767.

Health and Human Services Press Release, Nov. 17, 1989.

AMA Chemical Laboratory.

Elixir of Sulfanilamide Massengill. JAMA. 1937;109: 1531–1539.

Federal Food , Drug and Cosmetic Act, 21 U.S.C. 301–392, 1938.

Food and Drug Administration.

Requirements of Laws and Regulations Enforced by the U.S. Food and Drug Administration; 1979.

Hartman

L-Tryptophan: A rational hypnotic with clinical potential. Am J Psychiat. 1977;134(4):366–438.

The Washington Post.

72 Diet-Pill Ban Ignored Until Recent Deaths. September 5, 1990, p.A1.

Swygert

Maes

Sewell

Miller

Falk

Kilbourne

. Eosinophilia-Myalgia Syndrome — Results of national surveillance. JAMA. 1990;264(13):1698–1703.

Process For Producing L-Tryptophan, and a Pure Culture of a Microorganism Strain Used in Said Process. US Patent 4,363,875, Dec. 14, 1982.

10.

Process For Producing L-Tryptophan by Fermentation. US Patent 4,560,652, Dec. 24, 1985.

11.

What's Behind the L-Tryptophan Ban? In: Hand

, ed. Medical Sciences Bulletin. 1990;12(9):1–2.

12.

Atlanta Constitution.

A Pharmaceutical Detective Story. April 30, 1990, p.A1.

13.

Belongia

Hedberg

Gleich

An investigation of the cause of the Eosinophilia-Myalgia Syndrome associated with Tryptophan use. NEJM. 1990;323(6):357–365.

14.

Centers for Disease Control.

Analysis of L-tryptophan for the Etiology of Eosinophilia-Myalgia Syndrome. MMWR. 1990;39(34):589–591.

15.

Centers for Disease Control.

MMWR. 1990;39(43):789–790.

16.

Roberts

L-Tryptophan puzzle takes new twist. Science. 1990;249(4972):988.

17.

Mellon

Biotechnology, Human Disease, and the FDA. Science. 1990;250(4979):359–360.

When is a Drug Not a Drug? the L-Tryptophan Tragedy: Lessons to Be Learned

Abstract

Keywords

Get full access to this article

References